Loading...
Please wait, while we are loading the content...
Similar Documents
Systemic Treatments for Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Old Certainties and New Frontiers
| Content Provider | SAGE Publishing |
|---|---|
| Author | Rizzo, Alessandro Cusmai, Antonio Massafra, Raffaella Bove, Samantha Comes, Maria Colomba Fanizzi, Annarita Gadaleta-Caldarola, Gennaro Oreste, Donato Zito, Alfredo Giotta, Francesco Lorusso, Vito Palmiotti, Gennaro |
| Copyright Year | 2022 |
| Abstract | Epidermal growth factor receptor 2 (EGFR2, also known as HER2) overexpression and/or amplification confers a more aggressive clinical behavior but also represents a therapeutic opportunity for targeted therapies in breast cancer (BC). Over the last 2 decades, the prognosis of HER2-positive metastatic BC patients has improved due to the introduction of anti-HER2 agents including trastuzumab and novel, emerging drugs and combinations such as trastuzumab deruxtecan and tucatinib – trastuzumab - capecitabine. Herein, we provide a critical overview of current clinical recommendations and emerging treatment options for metastatic HER2-positive BC, especially focusing on recently presented and published clinical trials in this setting. |
| Related Links | https://journals.sagepub.com/doi/pdf/10.1177/10732748221106267?download=true |
| ISSN | 10732748 |
| Volume Number | 29 |
| Journal | Cancer Control (CCX) |
| e-ISSN | 15262359 |
| DOI | 10.1177/10732748221106267 |
| Language | English |
| Publisher | Sage Publications CA |
| Publisher Date | 2022-05-30 |
| Publisher Place | Los Angeles |
| Access Restriction | Open |
| Rights Holder | © The Author(s) 2022 |
| Subject Keyword | breast cancer trastuzumab deruxtecan trastuzumab emtansine metastatic breast cancer human epidermal growth factor receptor 2-positive tucatinib |
| Content Type | Text |
| Resource Type | Book Review |
| Subject | Hematology Oncology |
